Skip to main content

Table 1 Baseline characteristics and medical history

From: A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

  Prasugrel 5 mg n = 41* Placebo n = 21 p value
Age (mean, years) 32.9 31.5 0.553
Female, n (%) 21 (51.2) 9 (42.9) 0.598
Body Weight (mean, kg) 78.3 68.6 0.021
Hydroxyurea 18 9  
Sickle-cell Genotype, n (%)    >0.999
Hb S/ β0 thalassemia 2 (5.0) 1 (4.8)  
Hb S/ β + ˜ thalassemia 4 (10.0) 2 (9.5)  
Hb SC 10 (25.0) 5 (23.8)  
Hb SS 24 (60.0) 13 (61.9)  
Pain Intensity    0.473
Mean 1.8 2.4  
Minimum 0.0 0.0  
Median 0.0 2.0  
Maximum 9.0 7.0  
Medical History, n (%)    
Vaso-occlusive crisis 25 (61.0) 12 (57.1)  
Acute chest syndrome 9 (22.0) 2 (9.5)  
Hepatic sequestration 0 1 (4.8)  
Splenectomy 7 (17.1) 5 (23.8)  
Systemic hypertension 11 (26.8) 2 (9.5)  
Pulmonary hypertension 7 (17.1) 2 (9.5)  
Renal failure 1 (2.4) 0  
Hepatic disease 1 (2.4) 0  
Renal insufficiency 0 1 (4.8)  
Laboratory Values, mean (SD)    
Hemoglobin (g/L) 10.4 (1.8) 9.8 (2.0) 0.297
White Blood Cells (x109/L) 8.2 (3.4) 8.3 (2.7) 0.929
Platelets (x109/L) 310.6 (180.4) 340.5 (117.5) 0.561
  1. *1 patient was found not to have SCD but to have only β-thalassemia trait.
  2. Other than sequestration.